3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
32
Hodgkin Disease
29
Lymphoma
10
Sarcoma
7
Uveal Melanoma
5
Neoplasm Metastasis
4
Neoplasms
3
Leiomyosarcoma
2
HIV Infections
2
Solitary Fibrous Tumors
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Lymphoma, T-Cell, Peripheral
1
Immunotherapy
1
Hyperthermia
1
Hematologic Diseases
1
Carcinoma
1
Advanced Melanoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-Related Complex
1
Interventions
aldesleukin
16
Cyclophosphamide
14
fludarabine phosphate
11
Interleukin-2
11
fludarabine
10
Nivolumab
7
pembrolizumab
5
cemiplimab
5
Ipilimumab
5
Temozolomide
4
Fluorouracil
4
Aminolevulinic Acid
4
sonidegib
3
Surgical Procedures, Operative
3
Radiotherapy
3
zanolimumab
2
trametinib
2
talabostat
2
montanide ISA 51
2
dabrafenib
2
Whole-Body Irradiation
2
Tablets
2
Semaxinib
2
Radiation
2
Petrolatum
2
Peptides
2
MART-1 Antigen
2
Gefitinib
2
Eflornithine
2
Cisplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Skin Neoplasms
×
Dacarbazine
×
Clear all
NCT00070642
2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2
Completed
184 enrolled